で公開中です！ 詳しく見る
KNSAのアイコン

Kiniksa Pharmaceuticals
KNSA

78.59 USD
-1.35
1.69%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
78.54
-0.05
0.06%
1日
-1.69%
5日間
-1.76%
1か月
1.25%
3か月
28.6%
6か月
73.41%
年初来
87.07%
1年
101.93%
5年間
635.17%
10年間
303.65%
 

概要： Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

従業員数： 366

ヘルスケア 医薬品メーカー（スペシャリティ・ジェネリック）

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 50%
ニュートラル 37.5%
ネガティブ 12.5%
ポジティブ
Zacks Investment Research
29 日前
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
ポジティブ
Investors Business Daily
先月
Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.
Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
ニュートラル
GlobeNewsWire
先月
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
ポジティブ
Investors Business Daily
先月
Three Biotech Stocks Stick Out With Their Stellar Charts
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.
Three Biotech Stocks Stick Out With Their Stellar Charts
ネガティブ
Investors Business Daily
先月
Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan.
Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
ニュートラル
MarketBeat
2 か月前
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387.
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
ニュートラル
GlobeNewsWire
2 か月前
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
ポジティブ
Zacks Investment Research
2 か月前
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
ポジティブ
Zacks Investment Research
2 か月前
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
ニュートラル
Seeking Alpha
2 か月前
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています